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Abstract  
 Background: Atopic dermatitis, eczema, psoriasis are an important 
challenge for dermatology doctors. In order to have the best result in shorter 
time of treatment, it is necessary a collaboration with clinical pharmacists to 
have the right product, for the right type of skin, in the right amount 
according to the affected surface. It is very important to decide first which 
NSAID to use as topical therapy, second the type of formulation to use 
having at disposal Galenic preparations such as lotion, cream and unguent 
Objective: To study the efficacy and compliance of patients on three 
Galenic preparations. 
Method: A randomized, open group controlled trial. 198 patients were 
included in this trial to be treated either with lotion of 0.1%, cream of 0.1% 
or unguent 0.1% mometasone furoate (MF). The data were analyzed with 
chi-square test. 
Results: About 118 (59.6%) of patients were males and 80 (40.4%) were 
females. The male/female ratio was 1:0.67. After 28 days of treatment quite 
all patients were improved or had no signs of illness (lotion 97.6% improved, 
cream 80% absence of signs, unguent 63.0 % improved). 
The results after statistical analysis shows that there are much more 
possibility to become absent from signs using cream, rather than lotion or 
unguent [cream vs lotion 157 folds (P= 0.002) while unguent vs lotion 25 
folds (P<0.001)]. 
There were not noticed any treatment-related irritation from all three 
formulations.  
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Conclusion: All three formulations can improve the health status of patients 
with eczema, dermatitis or psoriasis. However cream gives faster and better 
clinical improvements compared to unguent or lotion. All three galenic 
preparations were well tolerated. 
 
Keywords: Formulation, topical formulation, eczema, efficacy  
 
Introduction 
 This trial is part of a wider study focused on the best practices in 
hospital pharmacy in Albania. The first part of the study was focused on 
formulation, preparation, stability and quality control of topical drugs. 
Pharmacists’ involvement with use of topical drugs consists on a close 
collaboration with medical doctors to prescribe the best medicine for 
individual patients. Topical corticosteroids, especially mometasone furoate, 
are used usually to treat eczema, atopic dermatitis or more rarely psoriasis 
(Valencia IC et al 2003). 
 The second part is the clinical trial to prove the efficacy. The 
cutaneous tolerance and cosmetic acceptability is an organic part of the 
efficacy of a topical preparation (Freeaman S. et al. 2002). So it is very 
important to evaluate that as well.  
 Ministry of Health in Albania is aiming to reduce the cost of 
medicines at “Mother Teresa” hospital and what better way can do than 
using all human capacity of professionals working there. No other healthcare 
professional is better equipped to formulate, prepare and monitor in 
collaboration with prescribers and consumers the best medicine for 
individual needs of patients. We’re aiming to create multidisciplinary teams 
of physicians and pharmacists for improving quality and safety in medication 
use. 
 
Patients, materials and methods 
 The study was a randomised, open clinical trial. The main diagnosis 
included in this study are eczema, atopic dermatitis and psoriasis.  
 Inclusion Criteria: at least 1 week without medication with 
corticosteroids and absence of secondary bacterial infections. The area to be 
treated should be quite the same, same skin type. 
 Exclusion criteria: the presence of another illness such as heavy renal 
or cardiovascular  disease, or polyvalent allergy. 
 Patients were included after giving written consent. They have been 
divided in 3 groups: 
 1st group was going to be treated with unguent 0.1% mometasone 
furoate (MF) from 14 - 28 days; 2nd group was going to be treated with 
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cream 0.1% mometasone furoate (MF) from 14 - 28 days; 3rd group with 
lotion 0.1% mometasone furoate (MF) from 14 - 28 days. 
 For each group has been evaluated the effect, patient’s compliance 
and safety for 2-4 weeks of treatment. 
 The data has been registered as in a rutine clinic documentation, in an 
approved format. There were recorded demographic data, signs of illness and 
their severity grading them according to the following scale: mild=0, 
moderate=1, severe=2. After 2 weeks of treatment we added also grade 
absent=3. The situation has been evaluated the day in which the patient came 
first to the clinic (day 0) and then in day 14 and day 28 of the treatment. It 
has been investigated the efficacy of lotion compared to cream or unguent 
prepared with the same concentration of MF treating eczema, atopic 
dermatitis or psoriasis. After 14 days of treatment the response to it was 
recorded as moderate, improved or absent. At the end of 28 days treatment 
patients were asked to give their opinion on the formulation regarding 
acceptability (feeling, staining skin or clothes, stickiness, spreadability). 
 The statistical analysis was chi-square test. 
 The clinical trial has been considered finished in the moment we had 
enough cases so that we could draw a conclusion. 
 This clinical trial was approved by National Committee of Bioethics, 
Ministry of Health in Albania. 
 
Results 
 There has been included 198 patients in this study. In this study 
participated 118 male and 80 female patients as it is illustrated in Figure 1. 
 
Male  Female 
Fig. 1. Spreading of patients according to gender 
 
 The main diagnosis included in this study are eczema (48.5%), atopic 
dermatitis (26.3%) and psoriasis (25.3%). The decision to choose such group 
of illnesses was made based on two facts: these are the target group treated 
with glucocorticosteroids, part of which is MF the active ingredient of our 
galenic formulations and we could have enough patients to get a significant 
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result from statistical point of view. Data regarding diagnosis and kind of 
treatment of the patients included in the study are shown in Table 1.  
Table 1. Spreading of patients in base of diagnosis and treatment 
Variable Number (n) Percentage (%) 
Diagnosis   
Dermatitis 52 26.3 
Eczema 96 48.5 
Psoriasis 50 25.3 
Treatment   
Lotion 84 42.4 
Cream 60 30.3 
Unguent 54 27.3 
Total 198 100.0 
Fig.2 shows that the majority of patients included in this study suffered eczema (48.5%) 
while those suffering atopic dermatitis or psoriasis were quite the same (26% and 25.3% 
respectively). 
 
 
Fig. 2. Spreading of patients in base of diagnosis 
 
 In Fig. 3 it is shown the distribution of patients in each group of 
treatment. So it can be noticed that patients suitable to be treated with lotion 
were 42.4%, those treated with cream 30.3% and those with unguent 27.3%. 
 
Lotion  Cream Unguent 
Type of treatment 
Fig. 3. Spreading of patients in base of treatment 
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 The assessment of severity of symptoms in day 0, 14 and 28 is shown 
in Table 2. 
*10 subjects didn’t return to the clinic 
 
 At the end of 14 days of treatment the efficacy of different 
formulations is showed in Table 3.   
* Number of subjects and percentage in brackets 
†  The overall value of P (statistical significance) according to chi-square test. 
 
 
Day 0  Day 14 Day 28 
Fig. 4. Spreading of patients based on results of the treatment per each period. 
 It can be noticed that in cream group the situation is much better, 
comparing to 2 other groups 20% is improved, while 80% had no more signs 
in the skin; in unguent group 63% is improved while 37% had no more 
signs; for the group of lotion the result is less optimistic 97.6% of patients 
treated with lotion are only improved, while 2.4% it can be said that had no 
more signs (P<0.001) (Fig. 6.) 
 
 
Table 2.  Spreading of patients based on results per each period of the treatment. 
 
Variable 
Period of  treatment 
Day 0 Day 14 Day 28* 
Number Percentage Number Percentage Number Percentage 
Health status       
Severe 198 100.0 6 3.0 - - 
Improved 0 0.0 192 97.0 126 67.0 
Absent - - - - 62 33.0 
Total 198 100.0 198 100.0 188 100.0 
Table 3. Percentage of healing according to the formulation used for 14 days. 
Variable 
Type of formulation  
Lotion Cream Unguent P† 
Health Status     
Improved 82 (97.6)* 12 (20.0) 34 (63.0) 
<0.001 Absent 2 (2.4) 48 (80.0) 20 (37.0) 
Total 84 (100.0) 60 (100.0) 54 (100.0) 
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Fig.5. The assessment of the efficacy of each formulation by “moderate” or “absent”, after 
28 days of treatment. 
 
 After controlling the age effect, subjects that use unguent has 25 folds 
more possibility to heal all signs, rather than those treated with lotion, while 
subjects treated with cream has 157 folds more possibility to heal all sign in 
the skin, rather than those treated with lotion (Table 4). In both cases the 
result is very significant (P=0.002 dhe P<0.001, respectively). 
Table 4. The evaluation of health status and type of formulation after 28 days of treatment; 
The value of OR controlled per age through models of binary logistic regression. 
Variable 2 Univariant  Limits 95% CI OR P* Lower Upper 
Type of formulation     
Lotion 1.00 (reference)    
Cream 156.6* < 0.001 17.070 1436.275 
Unguent 24.6 0.002 2.895 208.884 
* The result is statistically significant (P < 0.05) 
After concomitant control of age effect, type of formulation, diagnosis and gender there can 
be noticed important differences in the results (Table 5). 
 
Table 5. Concomitant evaluation of  type of formulation with health status after 28 
days treatment; OR controlled with age effect, type of formulation, diagnosis and 
gender through binar logistic regression models. 
Variable   Limits 95% CI OR P* Lower Upper 
Age 1.02 0.175 0.988 1.071 
Type of formulation     
Lotion 1.00 (reference) - - - 
Cream 404.2* < 0.001 27.791 5879.998 
Unguent 72.83* 0.001 5.518 961.322 
Diagnosis     
Dermatitis 1.00 (reference) - - - 
Eczema 11.715* 0.015 1.620 84.703 
Psoriasis 1.502 0.599 0.330 6.825 
Gender     
Male 1.00 (reference) - - - 
Female 0.364 0.180 0.083 1.594 
* the result is statistically significant (P < 0.05) 
Absent 
moderate 
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After the control of all these variables it can be noticed that patients 
treated with cream has much more possibilities to be healed comparing to 
those treated with lotion (OR = 404).  
 
Discussion 
 This study compared the efficacy of up to 4 weeks treatment with 
mometasone furoate 0.1% cream versus unguent or lotion prepared in a 
galenic laboratory. The study was a randomised open group evaluation. The 
study was conducted in “Mother Teresa” Universitary Hospital-Tirana, 
Albania and was included a total of 198 patients. Only 12 patients didn’t 
return to the clinic after 2 weeks of treatment.  
 Baseline showed that three treatment groups were well balanced in 
respect of number per group, age, gender, severity of signs and symptoms. 
However there were more cases of eczema than atopic dermatitis or 
psoriasis. Overall, all of three formulations were clinically effective and 
showed no  irritability in anyone of the patients included in this study. Also it 
is clear that the possibility to be healed using unguent is also increased, but 
not as much as those with cream. Cream is obviously much more superior 
(OR = 404).  
 At the end of the treatment 80% of patients in cream group were 
healed, whilst in unguent group only 37% and from lotion group only 2.4% 
(P<0.001). This result lead us to the decision to carry on the treatment of 
patients in unguent and lotion group of patients, but the following data are 
not included in this study. 
 The fact that cream gives better results than lotion or unguent is 
explained by different reasons:  
 First of all from the formulation point of view, the prepared cream is 
emulsion type O/W. After application it inverts, because of the evaporation 
of the water. So cream and unguent create a continuous oil film layer on the 
skin which contains the active ingredient as suspension. The water phase 
hydrates the corn layer of the skin, making it more easy to be penetrated by 
the other phase along with the active ingredient. In the mean time the oily 
phase can mix easily with the oil of the skin itself, taking along the way the 
lipophyle drug. The unguent having no water will penetrate more slowly the 
skin layers, while the lotion can hydrate very well the corn layer of the skin, 
but then it is stopped by the lipostructure of the other layers of the skin. [11] 
 Secondly the penetration ability and as a consequence the medical 
effect of a formulation it is affected also by its viscosity and the diffusion 
coefficient of the drug. The prepared cream has lower viscosity than the 
unguentm and so it penetrated more easily and it showed a better efficacy in 
shorter time.  
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 It is very interesting the fact that patients with eczema has more 
possibility to be healed, around 11.7 folds (P=0.015), compared to patients 
with atopic dermatitis. 
 So as a conclusion we can say that the efficacy of formulation cream 
is comparable with unguent, but patients compliance is much higher. In the 
other hand formulation cream produced a significantly more rapid clinical 
improvement than unguent or lotion.  Meanwhile the formulation lotion was 
much more acceptable from cosmetic point of view, compared to cream or 
unguent (P<0.05), but showed slower clinical improvements. 
 Our results support the view that cream formulation for topical use is 
much more superior to unguent or lotion one. 
 This is the first study in Albania to compare three galenic 
preparations for topical use in the same time. 
 We recommend to continue this study with pharmaco-economic 
evaluation. These two evaluations together would be of great help for the 
pharmacy of “Mother Teresa” Hospital Center and the strategy of MoH to 
low down the treatment costs. We recommend as well a continuous 
collaboration between medical doctors and pharmacists to optimise the 
treatment of patients in Albania. 
 
Conclusion 
 We can say that the efficacy of formulation cream is comparable with 
unguent, but patients compliance is much higher.  
 In the other hand formulation cream produced a significantly more 
rapid clinical improvement than unguent or lotion.   
 Meanwhile the formulation lotion was much more acceptable from 
cosmetic point of view, compared to cream or unguent (P<0.05), but showed 
slower clinical improvements. 
 Our results support the view that cream formulation for topical use is 
much more superior to unguent or lotion one. It gives higher efficacy in 
shorter time. 
 This is the first study in Albania, where an attempt to evaluate the 
efficacy of three galenic preparations at once was done.  
 We recommend to continue this study with pharmaco-economic 
evaluation. These two evaluations together would be of great help for the 
pharmacy of “Mother Teresa”  University Hospital Center and the strategy of 
MoH to low down the treatment costs. We recommend as well a continuous 
collaboration between physicians and pharmacists to optimise the treatment 
of patients in Albania. 
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